An Immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901

Josue Antonio Estrada, Chien-Yu Cheng, Shin-Yen Ku, Hui-Chun Hu, Hsiu-Wen Yeh, Yi-Chun Lin, Cheng-Pin Chen, Shu-Hsing Cheng, I-Feng Lin
doi: https://doi.org/10.1101/2022.02.26.22271364

Article usage

Article usage: March 2022 to April 2025

AbstractFullPdf
Mar 2022490319782
Apr 2022136226
May 2022142156
Jun 2022323042
Jul 2022162017
Aug 20228607
Sep 2022102020
Oct 2022104015
Nov 202278022
Dec 20224109
Jan 20234107
Feb 20234118
Mar 20236828
Apr 20234015
May 20233838
Jun 20232347
Jul 20232123
Aug 202328105
Sep 20232153
Oct 20231320
Nov 202330134
Dec 20231828
Jan 202422212
Feb 20241807
Mar 20241516
Apr 20241122
May 20241104
Jun 20241945
Jul 202410512
Aug 20241448
Sep 20242689
Oct 20241563
Nov 20241818
Dec 20241304
Jan 202511316
Feb 202518154
Mar 202539188
Apr 2025381619
Back to top
Posted March 01, 2022.
Download PDF
Data/Code
Email
An Immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
Josue Antonio Estrada, Chien-Yu Cheng, Shin-Yen Ku, Hui-Chun Hu, Hsiu-Wen Yeh, Yi-Chun Lin, Cheng-Pin Chen, Shu-Hsing Cheng, I-Feng Lin
medRxiv 2022.02.26.22271364; doi: https://doi.org/10.1101/2022.02.26.22271364
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area